Working… Menu
Trial record 1 of 1 for:    THRIVE AA-2
Previous Study | Return to List | Next Study

A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04797650
Recruitment Status : Recruiting
First Posted : March 15, 2021
Last Update Posted : November 24, 2021
Information provided by (Responsible Party):
Concert Pharmaceuticals

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : July 2022